West Pharmaceutical Services Inc.
WST | NYSE
$412.62
-$4.05 (-0.97%)
At close: Oct 30, 2026, 4:00 PM ET
$414.18
+$1.56 (+0.38%)
Pre-market:
Nov 2, 2026, 7:33 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 3.07B | 2.89B | 2.95B | 2.89B | 2.83B | 2.15B |
Cost of Revenue | 1.97B | 1.89B | 1.82B | 1.75B | 1.66B | 1.38B |
Gross Profit | 1.1B | 1B | 1.13B | 1.14B | 1.17B | 767.9M |
Operating Income | 617.4M | 594.6M | 710.9M | 763.5M | 758.7M | 419M |
Interest Income | 17.7M | 19.6M | 28M | 5.1M | 1M | 1.4M |
Pretax Income | 615.3M | 600.2M | 715.7M | 700.6M | 769M | 418.7M |
Net Income | 493.7M | 492.7M | 593.4M | 585.9M | 661.8M | 346.2M |
Selling & General & Admin | 393.1M | 338.5M | 353.4M | 316.9M | 361.9M | 302M |
Research & Development | 74.3M | 69.1M | 68.4M | 58.5M | 52.8M | 46.9M |
Other Expenses | 18.5M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 485.9M | 407.6M | 421.8M | 375.4M | 414.7M | 348.9M |
Interest Expense | 600K | 2.9M | 8.8M | 7.6M | 8.5M | 8.5M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.46B | 2.3B | 2.24B | 2.12B | 2.07B | 1.73B |
Income Tax Expense | 121.6M | 107.5M | 122.3M | 114.7M | 107.2M | 72.5M |
Shares Outstanding (Basic) | 72.3M | 73M | 74.3M | 74.4M | 74.4M | 73.9M |
Shares Outstanding (Diluted) | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M | 75.8M |
EPS (Basic) | 6.83 | 6.75 | 7.99 | 7.88 | 8.90 | 4.68 |
EPS (Diluted) | 6.80 | 6.69 | 7.88 | 7.73 | 8.67 | 4.57 |
EBITDA | 770.6M | 743.8M | 844.1M | 808.1M | 879.7M | 518.9M |
EBIT | 599.2M | 588.4M | 706.8M | 687.5M | 757.4M | 409.8M |
Depreciation & Amortization | 171.4M | 155.4M | 137.3M | 120.6M | 122.3M | 109.1M |
Add to Watchlist
Select watchlists to add or remove WST